Volumen: 20 # Number : 1
Publication Date : Enero - Abril Year: 2016
Ixaxomib: an oral proteasome inhibitor
Authors: Fantl D.
Abstract: Proteasome inhibitors (PI) are now part of the treatment
of patients with newly diagnosed myeloma and
relapsed or refractory disease. Its use is particularly
widespread in combination with other drugs, either
new one as IMIDs or older as cyclophosphamide or
melphalan. The introduction of ixazomib as an oral
PI can have a significant impact on the treatment of
myeloma, as this would allow all current oral regimens
the incorporation of a PI.
Key words: Multiple myeloma.
Proteasome inhibitor.
Ixazomib.
Pages :
|
